Volume 18, Number 5—May 2012
Dispatch
Hepatitis E Virus Infection among Solid Organ Transplant Recipients, the Netherlands
Suzan D. Pas, Rob A. de Man, Claudia Mulders, Aggie H.M.M. Balk, Peter T.W. van Hal, Willem Weimar, Marion P.G. Koopmans, Albert D.M.E. Osterhaus, and Annemiek A. van der Eijk
Table 2
Parameters in chronic HEV infections among SOT recipients, the Netherlands, 2000–2011*
| Parameter | Median | Range | ULN (F/M) |
|---|---|---|---|
| Peak alanine aminotransferase, U/L | 301 | 81–909 | 30/40 |
| Peak aspartate aminotransferase, U/L | 172 | 66–1016 | 30/36 |
| Peak gamma-glutamil transferase, U/L | 299 | 72–1740 | 34/49 |
| Peak bilirubin, μmol/L | 16 | 5–100 | 16/16 |
| Peak HEV RNA, cycle threshold values | 20.0 | 16.7–26.6 | NA |
| Period of HEV RNA positivity, mo | 16 | 6–55 | NA |
| Time between SOT and first HEV RNA–positive result, mo | 2.0 | –0.3 to 20.1 | NA |
| Time of HEV RNA positivity before HEV IgM positive, d | 32 | 0–826 | NA |
| Time of HEV RNA positivity before HEV IgG positive, d | 124 | 0–826 | NA |
*HEV, hepatitis E virus; SOT, solid organ transplant; ULN (F/M), upper limit of normal (female/male); NA, not applicable.
Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.